查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594060

代谢失调治疗药物市场：依疾病类型、产品类型划分 - 全球预测 2025-2030

Metabolic Disorders Therapeutics Market by Disease Type (Diabetes, Hypercholesterolemia, Lysosomal Storage Disease), Product (Globoid Leukodystrophy, Hepatic Encephalopathy, Metachromatic Leukodystrophy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年代谢紊乱药物市值为614.1亿美元，预计2024年将达667.8亿美元，复合年增长率为8.82%，到2030年将达到1110.4亿美元。

代谢紊乱药物市场范围广阔，包括以体内代谢异常化学反应为特征的疾病的治疗方法的开拓和应用。这包括糖尿病、高胆固醇症和溶小体贮积等疾病。这项需求是由于生活方式的改变、老化和遗传倾向等因素导致全世界代谢紊乱的盛行率不断增加。这些治疗剂应用于医院、诊所和居家医疗机构，其中包括低分子化合物和生技药品在内的药物是主要的干预方法。最终用途范围从儿科到成人患者，治疗需求根据疾病阶段而有所不同。

主要市场统计
基准年[2023] 614.1亿美元
预测年份 [2024] 667.8亿美元
预测年份 [2030] 1110.4亿美元
复合年增长率（%） 8.82%

市场成长是由生物技术的进步、医疗保健支出的增加和意识的提高所推动的。关键的成长要素包括新的治疗选择的出现，例如基因治疗和个人化医疗，它们可以提高疗效并减少副作用。人口老化和文明病的增加推动了需求。机会在于瞄准新兴市场，这些市场的医疗基础设施改善和经济成长正在增加医疗服务的覆盖范围。公司应专注于加强药物输送系统和患者依从性以发展业务。与当地医疗保健提供者和监管机构的合作也将促进这些地区的市场渗透。

然而，市场面临高昂的研发成本和严格的监管要求等限制，阻碍了快速商业化。由于代谢性疾病的复杂性，个人化诊断和治疗计划通常是一个挑战，增加了开发治疗方法所需的成本和时间。此外，专利到期以及与生物相似药的竞争也是主要问题。

可以透过专注于开发联合治疗和探索提供患者管理工具的数位健康解决方案来推动创新。用于早期检测和监测代谢异常的生物标记研究可以简化治疗方法并改善结果。该市场竞争激烈，但对于那些能够克服监管障碍、适应技术进步并在新治疗领域领先于患者需求的公司来说充满了机会。

市场动态：快速发展的代谢疾病治疗市场的关键市场洞察

供需的动态交互作用正在改变代谢紊乱药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 提高对代谢性疾病治疗的认识
    • 不断增长的人口中各种代谢疾病的盛行率
    • 改善代谢疾病的检查和诊断
  • 市场限制因素
    • 治疗费用上涨且无法报销
  • 市场机会
    • 增加开发新治疗方法的资金
    • 基因疗法治疗代谢疾病的潜力
  • 市场挑战
    • 严格的政府核准标准和规定

波特五力：驾驭代谢疾病药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解代谢紊乱治疗药物市场的外部影响

外部宏观环境因素在塑造代谢紊乱药物市场的动态表现方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解代谢紊乱治疗药物市场的竞争状况

代谢紊乱药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位基质代谢紊乱治疗市场供应商的绩效评估

FPNV定位矩阵是评估代谢性疾病药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘代谢紊乱治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，代谢紊乱药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高对代谢性疾病治疗的认识
      • 由于人口增长导致各种代谢疾病的传播
      • 改善代谢紊乱的测试和诊断
    • 抑制因素
      • 治疗费用上涨且无法报销
    • 机会
      • 增加开发新治疗方法的资金
      • 基因疗法治疗代谢性疾病的可能性
    • 任务
      • 严格的政府核准的标准和法规
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章代谢紊乱治疗药物市场：依疾病类型

  • 糖尿病
  • 高胆固醇症
  • 溶小体储积症
  • 肥胖

第七章代谢紊乱治疗药物市场：副产品

  • 球状脑白质营养不良
  • 肝性脑病变
  • 异染性脑白质营养不良

第八章北美与南美代谢紊乱治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区代谢失调治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲代谢紊乱治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics, Inc.
  • Astrazeneca PLC
  • Biocon
  • BioMarin Pharmaceutical Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Sanofi SA
  • Sigilon Therapeutics, Inc.
Product Code: MRR-0363DFE03688

The Metabolic Disorders Therapeutics Market was valued at USD 61.41 billion in 2023, expected to reach USD 66.78 billion in 2024, and is projected to grow at a CAGR of 8.82%, to USD 111.04 billion by 2030.

The scope of the Metabolic Disorders Therapeutics market is vast, involving the development and application of treatments for diseases characterized by abnormal chemical reactions in the body's metabolism. This includes conditions like diabetes, hypercholesterolemia, and lysosomal storage disorders. Necessity is driven by the increasing prevalence of metabolic disorders globally, spurred by factors such as lifestyle changes, aging populations, and genetic predispositions. These therapeutics find applications in hospitals, clinics, and homecare settings, with pharmaceuticals being the primary mode of intervention, including small molecules and biologics. End-use scope extends to pediatric and adult patients with varied treatment needs depending on disease progression.

KEY MARKET STATISTICS
Base Year [2023] USD 61.41 billion
Estimated Year [2024] USD 66.78 billion
Forecast Year [2030] USD 111.04 billion
CAGR (%) 8.82%

Market growth is being propelled by advancements in biotechnology, rising healthcare expenditure, and increased awareness. Key growth factors include the emergence of novel treatment options like gene therapy and personalized medicine, which offer improved efficacy and reduced side effects. Aging populations and increasing incidence of lifestyle-related disorders are driving demand. Opportunities lie in targeting emerging markets where healthcare infrastructure improvements and growing economies are widening access. Companies should focus on enhancing drug delivery systems and patient compliance for business growth. Partnerships with local healthcare providers and regulatory bodies can also facilitate market penetration in these regions.

However, the market faces limitations including high R&D costs and stringent regulatory requirements, which can hinder quick commercialization. The complexity of metabolic disorders often results in challenging diagnosis and individualized treatment plans, adding to the cost and time involved in therapeutic development. Moreover, patent expirations and competition from biosimilars pose significant challenges.

Innovation can be driven by focusing on developing combination therapies and exploring digital health solutions that provide patient management tools. Research into biomarkers for early detection and monitoring of metabolic disorders could streamline treatment approaches and improve outcomes. The nature of the market is competitive but ripe with opportunities for those that can navigate regulatory hurdles, adapt to technological advancements, and anticipate patient needs in emerging therapeutic areas.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Metabolic Disorders Therapeutics Market

The Metabolic Disorders Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness regarding the treatment of metabolic disorders
    • Prevalence of various metabolic diseases in the growing population
    • Improvements in metabolic disorder testing and diagnosis
  • Market Restraints
    • High cost of therapeutics and lack of reimbursements
  • Market Opportunities
    • Rise in the funding for the development of novel therapeutic approaches
    • Potential of gene therapy for metabolic disorder treatment
  • Market Challenges
    • Strict government approval standards and regulations

Porter's Five Forces: A Strategic Tool for Navigating the Metabolic Disorders Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Metabolic Disorders Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Metabolic Disorders Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Metabolic Disorders Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Metabolic Disorders Therapeutics Market

A detailed market share analysis in the Metabolic Disorders Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Metabolic Disorders Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Metabolic Disorders Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Metabolic Disorders Therapeutics Market

A strategic analysis of the Metabolic Disorders Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Metabolic Disorders Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Astrazeneca PLC, Biocon, BioMarin Pharmaceutical Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck KGaA, Novo Nordisk A/S, Sanofi S.A., and Sigilon Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Metabolic Disorders Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Diabetes, Hypercholesterolemia, Lysosomal Storage Disease, and Obesity.
  • Based on Product, market is studied across Globoid Leukodystrophy, Hepatic Encephalopathy, and Metachromatic Leukodystrophy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness regarding the treatment of metabolic disorders
      • 5.1.1.2. Prevalence of various metabolic diseases in the growing population
      • 5.1.1.3. Improvements in metabolic disorder testing and diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics and lack of reimbursements
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in the funding for the development of novel therapeutic approaches
      • 5.1.3.2. Potential of gene therapy for metabolic disorder treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Strict government approval standards and regulations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Metabolic Disorders Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Hypercholesterolemia
  • 6.4. Lysosomal Storage Disease
  • 6.5. Obesity

7. Metabolic Disorders Therapeutics Market, by Product

  • 7.1. Introduction
  • 7.2. Globoid Leukodystrophy
  • 7.3. Hepatic Encephalopathy
  • 7.4. Metachromatic Leukodystrophy

8. Americas Metabolic Disorders Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Metabolic Disorders Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amicus Therapeutics, Inc.
  • 4. Astrazeneca PLC
  • 5. Biocon
  • 6. BioMarin Pharmaceutical Inc.
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche Ltd
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck KGaA
  • 12. Novo Nordisk A/S
  • 13. Sanofi S.A.
  • 14. Sigilon Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METABOLIC DISORDERS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023